Core Insights - Urbana Corporation has been recognized on The Globe and Mail's 2026 Report on Business magazine's seventh annual Women Lead Here list, marking its fourth recognition for executive gender diversity [2][6]. Company Overview - Urbana Corporation is a diversified corporation focusing on financial services, information services, and innovative technologies, aiming for capital appreciation through private investments and publicly traded securities [6]. Gender Diversity Recognition - The Women Lead Here benchmark, established in 2020, evaluates Canadian corporations based on the ratio of female-identifying to male-identifying executives in top leadership roles, highlighting companies that have made progress in executive gender parity [3][5]. - For the 2026 ranking, approximately 500 large publicly traded Canadian companies were analyzed, resulting in 85 companies earning the Women Lead Here seal, with an average of 48% of executive roles held by female-identifying individuals [5][6]. Leadership Commentary - Thomas S. Caldwell, Chair of Urbana Corporation, expressed gratitude for the contributions of female executives, emphasizing the commitment of the company's team [4].

We expect to release the Q1 2026 interim results of DSV A/S in the morning of 29 April 2026. A webcast and conference call will be held at 11:00 am CEST. At the conference call, Jens H. Lund, Group CEO, and Michael Ebbe, Group CFO, will present the Q1 2026 Interim Financial Report. The presentation will be followed by a Q&A session. Date: 29 April 2026Time: 11:00 am CEST To attend the webcast presentation, please go to Webcast presentation - DSV Interim Financial Report Q1 2026 or go to https://investor.ds ...

Core Points - Leading Edge Materials Corp. will hold its Annual General Meeting of Shareholders on April 23, 2026, at 9:00 am Vancouver Time [1] - The record date for the Meeting is March 19, 2025, and related materials are available on SEDAR and the company's website [2] - Shareholders holding Euroclear Registered Securities will receive a voting instruction form from Computershare Sweden, which must be returned according to provided instructions [3] Meeting Agenda - The agenda includes receiving the CEO's report, considering financial statements for the year ended October 31, 2025, and electing directors [5] - The meeting will also address the appointment of auditors and the ratification of the stock option plan [5] - Additional business may be transacted as permitted [5] Company Overview - Leading Edge Materials is focused on developing critical raw material projects in the European Union, linked to high-growth technologies such as lithium-ion batteries and permanent magnets [6] - The company's portfolio includes the Woxna Graphite mine, Norra Kärr Heavy Rare Earth Elements project, and Bihor Sud Nickel Cobalt exploration alliance [6] - The company is listed on multiple exchanges, including TSXV, OTCQB, and Nasdaq First North [8]

Core Viewpoint - Iterum Therapeutics plc has filed a petition for winding up the company due to financial difficulties and inability to comply with Nasdaq listing requirements, leading to the appointment of Joint Provisional Liquidators [1][2][3] Financial Situation - The company cited limited cash resources and restrictions on raising additional capital as primary reasons for pursuing liquidation [3] - The inability to regain compliance with Nasdaq listing requirements was a significant factor in the decision [3] - The company has incurred significant expenses related to the commercialization of its product ORLYNVAH™ amidst modest sales [3] Strategic Alternatives - Iterum engaged in discussions with two potential counterparties regarding the acquisition of sulopenem but could not finalize any agreements due to time constraints and limited cash runway [3] - The Board concluded that there were no reasonable avenues for alternative strategic transactions outside of liquidation [3] Liquidation Process - The High Court in Ireland will hear the winding up petition on April 13, 2026, which, if approved, will lead to the dissolution of the company [2] - Joint Provisional Liquidators will oversee the wind down of Iterum's subsidiaries [4] Product Information - Iterum's primary product, ORLYNVAH™, is an oral antibiotic aimed at treating uncomplicated urinary tract infections caused by specific bacteria [7][9] - The product has received FDA approval and designations for its formulations, indicating its potential in addressing multi-drug resistant infections [7]

Core Viewpoint - Maris-Tech Ltd. has initiated a pilot program in the U.S. to enhance battlefield awareness capabilities for armored vehicle crews through integrated multi-sensor technology [1][2]. Group 1: Pilot Program Details - The pilot program aims to integrate Maris-Tech's technologies to improve operational visibility for armored vehicle crews [2]. - The Diamond Ultra platform will be combined with the Peridot night-vision module and a thermal camera dome to provide multi-directional sensing [3]. - The integrated systems are designed to deliver 3D situational awareness by fusing multiple sensor inputs into a unified operational view [3][4]. Group 2: Potential Impact and Opportunities - Successful execution of the pilot could lead to broader deployment of Maris-Tech's situational awareness solutions within the U.S. defense market and other global defense programs [5]. - The pilot reflects the growing recognition of Maris-Tech's technologies and the increasing demand for integrated visibility solutions for armored platforms [6]. Group 3: Company Overview - Maris-Tech specializes in AI-powered edge video solutions for defense and security operations, enabling real-time situational awareness and intelligence gathering [7]. - The company's platforms are utilized across various applications, including UAVs, UGVs, and armored vehicles, supporting missions that require ultra-low-latency video processing and onboard AI analytics [7].

Core Insights - Silynxcom Ltd. has received a purchase order exceeding $1.1 million from a military force in the Middle East for its Tactical Systems, indicating strong demand for its products [1][2]. Company Overview - Silynxcom Ltd. specializes in the development, manufacturing, marketing, and sales of ruggedized tactical communication headset devices and accessories, which are field-tested and combat-proven [3]. - The company's In-Ear Headsets are utilized in various high-stakes environments, including combat, riot control, and training scenarios, providing seamless integration with professional-grade ruggedized radios [3]. - Silynxcom's products are designed to ensure clear communication while protecting users from hazardous sounds, offering 360° situational awareness [3]. - The company collaborates closely with military and law enforcement customers to enhance product functionality and quality based on real-world feedback [3].

Core Viewpoint - SB Financial Group, Inc. is set to release its first quarter 2026 financial results on April 23, 2026, and will hold a conference call on April 24, 2026, to discuss these results [1]. Company Overview - SB Financial Group is a diversified financial services holding company based in Defiance, Ohio, operating through the State Bank & Trust Company and SBFG Title, LLC [3]. - The State Bank offers a comprehensive range of financial services, including wealth management, private client services, mortgage banking, and commercial and agricultural lending, with a total of 27 offices across Ohio and Indiana [3]. - SB Financial's common stock is traded on the NASDAQ Capital Market under the ticker symbol "SBFG" [3]. Conference Call Details - Interested parties can access the conference call by dialing 888-338-9469 and requesting the "SB Financial Group Conference Call" [2]. - The conference call will also be available via live webcast at ir.yourstatebank.com, with an audio replay accessible on the SB Financial Group website [2].

Core Viewpoint - AnaptysBio, Inc. has announced the spin-off of First Tracks Biotherapeutics, Inc., which will begin trading on Nasdaq under the ticker symbol "TRAX" on April 20, 2026, aiming to focus on developing next-generation antibody therapeutics for autoimmune and inflammatory diseases [1][2]. Group 1: Spin-off Details - The spin-off will allow AnaptysBio to distribute all shares of First Tracks Bio common stock to its stockholders, with a record date set for April 6, 2026, where stockholders will receive one share of First Tracks Bio for each share of AnaptysBio held [5][9]. - First Tracks Bio will launch with an initial cash balance of $180 million, which includes $100 million from Anaptys and $80 million from a private placement [6][7]. Group 2: Leadership and Management - Daniel Faga will serve as the president and CEO of First Tracks Bio, while also holding the CEO position at AnaptysBio [2][7]. - The executive leadership team will include Paul Lizzul, M.D., Ph.D. as CMO and Ben Stone as CBO, with Ajim Tamboli expected to join as CFO on April 20, 2026 [7]. Group 3: Development Pipeline - First Tracks Bio will focus on three lead development-stage assets: ANB033, a CD122 antagonist in a Phase 1b trial for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial for rheumatoid arthritis; and ANB101, a BDCA2 modulator in a Phase 1a trial [1].

Core Insights - ASUS Republic of Gamers (ROG) has launched the new 2026 ROG Zephyrus lineup in Canada, featuring the Zephyrus Duo, Zephyrus G14, and Zephyrus G16, all equipped with next-generation performance capabilities and premium portability for gamers and professionals [3][4]. Product Features - The Zephyrus Duo is the world's first 16-inch dual-screen gaming laptop, featuring two 3K ROG Nebula HDR OLED touchscreens with a total diagonal screen space of over 21 inches, a 0.2ms response time, and a 120Hz refresh rate [5][6]. - The Zephyrus G14 and G16 models are equipped with Intel Core Ultra processors and NVIDIA GeForce RTX 50 Series Laptop GPUs, providing high performance for gaming and content creation [3][10]. - The entire lineup supports advanced AI capabilities, with up to 50 TOPS of NPU compute performance, enhancing user experiences with local AI functionalities [10]. Design and Portability - The new Zephyrus models feature a premium CNC-milled aluminum chassis, with the G14 weighing just 1.5 kg and the G16 under 2 kg, making them highly portable [13]. - The Zephyrus Duo includes a detachable magnetic keyboard that can be used wirelessly, enhancing flexibility in various operating modes [8][9]. Display Technology - All models in the lineup feature ROG Nebula HDR displays, with the G14 offering a 14-inch 3K 120Hz OLED display and the G16 a 16-inch 2.5K 240Hz OLED panel, both providing exceptional color accuracy and brightness [15][16]. Availability and Pricing - Pre-orders for the new ROG Zephyrus models began on March 27, 2026, with shipping starting on April 17, 2026. The pricing for the Zephyrus Duo starts at C$8,999, while the G14 and G16 start at C$4,299 and C$4,099 respectively [4][17][24].

Core Viewpoint - AnaptysBio, Inc. has announced a $100 million stock repurchase plan and provided a business update following the planned spin-off of First Tracks Biotherapeutics, focusing on maximizing shareholder value through financial collaborations and operational efficiency [1][4][8]. Stock Repurchase Plan - The company has authorized a stock repurchase plan allowing for the repurchase of up to $100 million of its outstanding common stock, with the plan set to expire on December 31, 2026 [1][7][11]. - The repurchase will occur through open market transactions or other means in accordance with relevant regulations [7][11]. Spin-Off Details - AnaptysBio will spin off its biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 [2][8]. - Post spin-off, Anaptys will manage financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return value to shareholders [2][4][8]. Financial Position and Operating Model - The company anticipates having approximately $140-$145 million in net cash and investments after the spin-off [2][8]. - Anaptys plans to operate with a virtual model, maintaining fewer than 10 full-time equivalents (FTEs) and expects annual operating expenses of less than $10 million, targeting a greater than 95% EBIT margin [9]. Leadership Changes - Susannah Gray has been appointed to the Board of Directors, bringing over 30 years of biopharmaceutical experience, including her previous role as CFO of Royalty Pharma [3][9]. - Daniel Faga will continue as CEO of Anaptys post spin-off, with a search initiated for a new CFO [9].